USA
Analytical Standards
Controlled Research Environment
Research Product
Hexarelin
1. Product Overview
Hexarelin is a synthetic hexapeptide that has attracted scientific interest in research involving growth hormone secretagogue receptors (GHS-R), endocrine signaling pathways, peptide receptor interactions, and growth hormone regulatory mechanisms. Ongoing studies continue to explore its role in peptide-mediated cellular communication, metabolic regulation, and growth hormone-related biological processes. Hexarelin is supplied as a lyophilized research peptide and undergoes analytical testing to verify identity, purity, and consistency.
Manufactured in a controlled research environment, this product is intended exclusively for laboratory and scientific research applications.
2. Specifications
| Product Name | Hexarelin | Testing Method | HPLC |
|---|---|---|---|
| Synonym | Examorelin | Storage Condition | 2-8C |
| Format | Lyophilized Powder | Shelf Life | 24 Months |
| Content | 5 mg per vial | Manufacturing Standard | GMP Standard Research Environment |
| Purity | >=99% HPLC | Country of Origin | USA |
| Appearance | White to Off White Lyophilized Powder | Intended Use | Research Use Only |
3. Research Summary
Hexarelin is a synthetic hexapeptide classified as a growth hormone secretagogue (GHS). It has been extensively studied for its interaction with growth hormone secretagogue receptors (GHS-R) and endocrine signaling pathways involved in growth hormone regulation. Research has explored its role in peptide receptor activation, cellular signaling mechanisms, neuroendocrine function, and metabolic pathway investigations.
Preclinical and laboratory studies have examined Hexarelin's interaction with growth hormone-related biological systems, cardiovascular research models, and cellular response mechanisms. Ongoing scientific investigations continue to explore its broader role within endocrine and peptide signaling research.
4. Scientific References
- Bowers CY, Momany FA, Reynolds GA, Hong A. Structure-activity relationships of growth hormone-releasing peptides. Endocrinology. 1984;114(5):1537-1545.
- Papotti M, Ghè C, Cassoni P, et al. Growth hormone secretagogue binding sites in peripheral human tissues. Journal of Clinical Endocrinology & Metabolism. 2000;85(10):3803-3807.
- Locatelli V, Rossoni G, Schweiger F, et al. Growth hormone-independent cardioprotective effects of Hexarelin in experimental models. Endocrinology. 1999;140(9):4024-4031.
- Muccioli G, Papotti M, Locatelli V, Ghigo E, Deghenghi R. Binding of growth hormone secretagogues to specific receptors in central and peripheral tissues. European Journal of Endocrinology. 2001;144(4):311-320.
- Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. European Journal of Endocrinology. 1997;136(5):445-460.
Disclaimer: This product is intended strictly for research use only. It is not intended for human consumption, clinical application, diagnostic procedures, therapeutic use, veterinary use, or household use. The information provided is for scientific and educational reference purposes only and should not be interpreted as medical advice, treatment guidance, or usage instructions. This product should be handled only by qualified professionals trained in laboratory practices. Purchasers and end users are solely responsible for ensuring compliance with all applicable laws, regulations, and institutional requirements governing the purchase, storage, handling, and use of research materials.
